新型支气管扩张剂S1226治疗急性哮喘的IIa期概念验证试验
该IIa期随机双盲安慰剂对照交叉试验在12例轻度过敏性哮喘受试者中评估新型支气管扩张剂S1226(8% CO2)在过敏原诱导支气管收缩后的安全性、耐受性和疗效。结果显示S1226安全耐受良好,能维持血氧正常并显著改善FEV1恢复,但早期恢复率差异未达统计学显著。
要点
- S1226在过敏原激发后维持血氧正常,安慰剂组血氧下降(P=0.028)。
- S1226组FEV1随时间恢复显著优于安慰剂(P=0.04)。
- 所有不良事件非严重、轻微且短暂,无显著安全问题。
核心结论
- S1226在轻度过敏性哮喘受试者中安全、耐受良好,并提供支气管扩张和改善血氧。
- 需进一步研究优化治疗反应。
研究设计与样本
- IIa期概念验证、安慰剂对照、随机、双盲、交叉、单剂量临床试验。
- 12例轻度过敏性哮喘受试者,在过敏原诱导早期哮喘反应后经雾化给予S1226(8% CO2)。
主要发现
- 无显著安全问题,所有不良事件非严重、轻微且短暂。
- 安慰剂组过敏原吸入后外周血氧随时间显著下降,S1226组维持正常(P=0.028),治疗开始后5分钟效应最大(P<0.001)。
- S1226组FEV1随时间恢复显著优于安慰剂(P=0.04)。
- 早期时间点(5、10、15分钟)FEV1逆转≥12%的恢复率S1226更快但未达统计学显著(P=0.272)。
关键数值与推荐
- 主要安全性终点:不良事件、生命体征、脉搏血氧饱和度、 spirometry。
- 疗效终点:FEV1随时间变化的支气管扩张反应、早期哮喘反应FEV1曲线下面积、应答者状态(过敏原激发后FEV1改善12%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluates a novel bronchodilator, S1226, for its efficacy in reversing allergen-induced bronchoconstriction in subjects with mild, allergic asthma. S1226 is a new class of bronchodilator that is an aerosol/vapor/gas mixture combining pharmacological and biophysical principles for a novel mode of action. It contains a potent bronchodilator gas (carbon dioxide or CO2) and nebulized perflubron (a synthetic surfactant possessing mucolytic properties). It has demonstrated rapid reversal of allergen-induced bronchoconstriction in an ovine study model. METHODS: This was a phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover single-dose clinical trial to evaluate the safety, tolerability, and efficacy of S1226 (8% CO2) administered by nebulization following an allergen-induced early asthmatic response in 12 subjects with mild, allergic asthma. Primary safety endpoints were adverse events, vital signs, pulse oximetry, and spirometry. Efficacy endpoints included bronchodilator response (measured as the forced expiratory volume in 1 s or FEV1) over time, the area under the curve of FEV1 for the early asthmatic response over time, and achievement of responder status, defined as a 12% improvement after the allergen challenge. RESULTS: No significant safety issues were observed. All adverse events were non-serious, mild, and transient. There was a statistically significant decrease in peripheral blood oxygenation levels over time in the placebo group following allergen inhalation, whereas blood oxygenation was maintained at normal levels in the S1226-treated subjects (P = 0.028). This effect was greatest 5 min after start of treatment (P < 0.001). The recovery rate was faster but not significantly so (P = 0.272) for S1226 compared to the placebo at earlier time points (5, 10, and 15 min), as assessed by ≥12% reversal of FEV1. The recovery of FEV1 over time was significantly greater (P = 0.04) with S1226 compared to the placebo. CONCLUSIONS: S1226 was safe, tolerated well, and provided bronchodilation and improved blood oxygenation in subjects with mild atopic asthma following allergen-induced bronchoconstriction. Additional studies to optimize the therapeutic response are indicated. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02334553 . Registered on 12 November 2014.
引用
- Swystun V, Green FHY, Dennis JH, et al. A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma. Trials. 2018. PMID: 29914544. doi:10.1186/s13063-018-2720-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。